Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALNA NASDAQ:BBI NASDAQ:KRBP NASDAQ:PTE NASDAQ:WINT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNAAllena Pharmaceuticals$0.07$0.06▼$1.17$37K1.1315.69 million shs96,558 shsBBIBrickell Biotech$0.86$2.21▼$37.35$6.75M0.02206,730 shs31,300 shsKRBPKiromic BioPharma$1.16$0.16▼$3.32$330K1.6611,347 shs107,749 shsPTEPolarityTE$0.37$0.20▼$1.90$1.78M1.15249,591 shs8.50 million shsWINTWindtree Therapeutics$0.06-1.1%$0.50$0.06▼$178.00$1.80M0.575.51 million shs681,077 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNAAllena Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BBIBrickell Biotech0.00%0.00%0.00%0.00%0.00%KRBPKiromic BioPharma0.00%0.00%0.00%0.00%-88.33%PTEPolarityTE0.00%0.00%0.00%0.00%0.00%WINTWindtree Therapeutics0.00%-16.16%-88.05%-89.80%-99.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNAAllena Pharmaceuticals$0.07$0.06▼$1.17$37K1.1315.69 million shs96,558 shsBBIBrickell Biotech$0.86$2.21▼$37.35$6.75M0.02206,730 shs31,300 shsKRBPKiromic BioPharma$1.16$0.16▼$3.32$330K1.6611,347 shs107,749 shsPTEPolarityTE$0.37$0.20▼$1.90$1.78M1.15249,591 shs8.50 million shsWINTWindtree Therapeutics$0.06-1.1%$0.50$0.06▼$178.00$1.80M0.575.51 million shs681,077 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNAAllena Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BBIBrickell Biotech0.00%0.00%0.00%0.00%0.00%KRBPKiromic BioPharma0.00%0.00%0.00%0.00%-88.33%PTEPolarityTE0.00%0.00%0.00%0.00%0.00%WINTWindtree Therapeutics0.00%-16.16%-88.05%-89.80%-99.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALNAAllena Pharmaceuticals 0.00N/AN/AN/ABBIBrickell Biotech 0.00N/AN/AN/AKRBPKiromic BioPharma 0.00N/AN/AN/APTEPolarityTE 0.00N/AN/AN/AWINTWindtree Therapeutics 2.00Hold$350.00571,795.42% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALNAAllena PharmaceuticalsN/AN/AN/AN/A$0.23 per shareN/ABBIBrickell Biotech$4.64M0.00N/AN/A$9.75 per share0.00KRBPKiromic BioPharmaN/AN/AN/AN/A($8.29) per shareN/APTEPolarityTE$810K0.00N/AN/A$2.30 per share0.00WINTWindtree TherapeuticsN/AN/AN/AN/A$0.98 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALNAAllena Pharmaceuticals-$48.66MN/A0.00N/AN/AN/A-287.46%-146.58%N/ABBIBrickell Biotech-$39.47M-$13.52N/AN/AN/A-643.48%-156.10%-128.23%N/AKRBPKiromic BioPharma-$26.90M-$3.50N/AN/AN/AN/AN/A-277.46%N/APTEPolarityTE-$7.83M-$3.28N/AN/AN/AN/A-106.08%-76.91%N/AWINTWindtree Therapeutics-$1.79M-$823.47N/AN/AN/AN/A-207.34%-50.19%11/25/2025 (Estimated)Latest PTE, KRBP, WINT, BBI, and ALNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025WINTWindtree Therapeutics-$99.00-$3.06+$95.94-$3.06$3.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALNAAllena PharmaceuticalsN/AN/AN/AN/AN/ABBIBrickell BiotechN/AN/AN/AN/AN/AKRBPKiromic BioPharmaN/AN/AN/AN/AN/APTEPolarityTEN/AN/AN/AN/AN/AWINTWindtree TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALNAAllena PharmaceuticalsN/A1.581.58BBIBrickell BiotechN/A6.366.36KRBPKiromic BioPharmaN/A0.160.22PTEPolarityTEN/A4.114.11WINTWindtree TherapeuticsN/A0.430.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALNAAllena Pharmaceuticals7.33%BBIBrickell BiotechN/AKRBPKiromic BioPharma10.91%PTEPolarityTE11.75%WINTWindtree Therapeutics29.33%Insider OwnershipCompanyInsider OwnershipALNAAllena Pharmaceuticals3.70%BBIBrickell Biotech4.53%KRBPKiromic BioPharma20.59%PTEPolarityTE5.40%WINTWindtree Therapeutics0.15%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALNAAllena Pharmaceuticals35122.08 million117.57 millionNot OptionableBBIBrickell Biotech162.87 million2.74 millionNot OptionableKRBPKiromic BioPharma601.57 million1.22 millionNot OptionablePTEPolarityTE427.38 million6.98 millionOptionableWINTWindtree Therapeutics3029.33 million3.66 millionNot OptionablePTE, KRBP, WINT, BBI, and ALNA HeadlinesRecent News About These CompaniesShort Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Drops By 70.8%September 13 at 2:55 AM | americanbankingnews.comShort Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Drops By 36.9%September 7, 2025 | americanbankingnews.comWindtree Therapeutics Approves Key Financial Structure ChangesSeptember 3, 2025 | msn.comWindtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder MeetingSeptember 2, 2025 | markets.businessinsider.comWindtree Therapeutics, Inc. Stockholders Approve Strategic Shift Toward Environmental Services and Biotech PartnershipsSeptember 2, 2025 | quiverquant.comQWarrington’s Windtree Therapeutics Faces Uncertain Future After NASDAQ DelistingAugust 27, 2025 | msn.comBNB Treasury Firm Windtree Therapeutics Plunges 77% After Nasdaq Delisting NoticeAugust 22, 2025 | thecurrencyanalytics.comTBNB treasury company plunges 77% after Nasdaq delisting noticeAugust 22, 2025 | cointelegraph.comBNB hits new all-time high even as treasury company Windtree Therapeutics faces Nasdaq delistingAugust 20, 2025 | fxstreet.comNasdaq to Delist BNB Treasury Firm Windtree Therapeutics, Stock Crashes 76%August 20, 2025 | coingape.comCWindtree Therapeutics Faces Nasdaq Delisting NoticeAugust 20, 2025 | msn.comWindtree Therapeutics Delays Q2 2025 Report FilingAugust 14, 2025 | tipranks.comWindtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025August 11, 2025 | globenewswire.comWindtree Therapeutics Terminates SEISMiC-C Clinical StudyAugust 11, 2025 | theglobeandmail.comWindtree Advances Istaroxime Toward Global Phase 3 Following Positive Interim Study ResultsAugust 7, 2025 | msn.comWindtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock PatientsAugust 5, 2025 | taiwannews.com.twTWindtree Therapeutics Cuts Preferred Stock by Over 99% Ahead of Crypto Strategy RolloutJuly 30, 2025 | msn.comWindtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and RedemptionJuly 29, 2025 | globenewswire.comWindtree Therapeutics Bets $520M on Binance Coin in Unprecedented Crypto PivotJuly 26, 2025 | thecurrencyanalytics.comTWindtree Therapeutics Commits Up to $700 Million to Build BNB Treasury Following All-Time HighJuly 26, 2025 | techstory.inTNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNVIDIA Stock Could Pull Back in September, But Don’t Bet on ItBy Thomas Hughes | August 28, 2025Top 5 September Stock Picks: Market Tailwinds Drive New MomentumBy Thomas Hughes | September 1, 2025What to Expect From the Q3 Reporting SeasonBy Thomas Hughes | September 3, 20253 Gold ETFs That Could Surge If the Fed Cuts Rates This MonthBy Jordan Chussler | September 1, 2025Microsoft Stock: Bullish Bets Pile Up Before SeptemberBy Chris Markoch | August 18, 2025PTE, KRBP, WINT, BBI, and ALNA Company DescriptionsAllena Pharmaceuticals NASDAQ:ALNAAllena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.Brickell Biotech NASDAQ:BBIBrickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.Kiromic BioPharma NASDAQ:KRBPKiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.PolarityTE NASDAQ:PTEPolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.Windtree Therapeutics NASDAQ:WINT$0.06 0.00 (-1.13%) As of 09/12/2025 03:59 PM EasternWindtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
